Home > > > > > Report Detail

Guillain-Barre Syndrome (GBS) - Market Insight, Epidemiology and Market Forecast - 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 100
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Guillain-Barre Syndrome (GBS) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Guillain-Barre Syndrome (GBS) epidemiology and market outlook for the 7MM.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Guillain-Barre Syndrome (GBS) Understanding and Treatment Algorithm

The market report provides the overview of the Guillain-Barre Syndrome (GBS) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Guillain-Barre Syndrome (GBS) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Guillain-Barre Syndrome (GBS) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Guillain-Barre Syndrome (GBS) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Guillain-Barre Syndrome (GBS) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Guillain-Barre Syndrome (GBS) market.

Guillain-Barre Syndrome (GBS) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Guillain-Barre Syndrome (GBS) Report Insights

- Patient Population in Guillain-Barre Syndrome (GBS)

- Therapeutic Approaches in Guillain-Barre Syndrome (GBS)

- Guillain-Barre Syndrome (GBS) Pipeline Analysis

- Guillain-Barre Syndrome (GBS) Market Size and Trends

- Guillain-Barre Syndrome (GBS) Market Opportunities

- Impact of upcoming Therapies in Guillain-Barre Syndrome (GBS)

Guillain-Barre Syndrome (GBS) Report Key Strengths

- 10 Year Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Drugs Uptake

- Highly Analyzed Market

- Key Cross Competition

Guillain-Barre Syndrome (GBS) Report Assessment

- Current Treatment Practices in Guillain-Barre Syndrome (GBS)

- Unmet Needs in Guillain-Barre Syndrome (GBS)

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

- The report will help to develop Business Strategies by understanding the trends shaping and driving the Guillain-Barre Syndrome (GBS) market

- Organize sales and marketing efforts by identifying the best opportunities for Guillain-Barre Syndrome (GBS) market

- To understand the future market competition in the Guillain-Barre Syndrome (GBS) market.

Guillain-Barre Syndrome (GBS) - Market Insight, Epidemiology and Market Forecast - 2028

Table of Contents

1. Report Introduction
2. Guillain-Barre Syndrome (GBS) Market Overview at a Glance
2.1. Market Share Distribution of Guillain-Barre Syndrome (GBS) in 2016
2.2. Market Share Distribution of Guillain-Barre Syndrome (GBS) in 2028
3. Disease Background and Overview: Guillain-Barre Syndrome (GBS)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Guillain-Barre Syndrome (GBS) in 7MM
4.3. Total Prevalent Patient Population of Guillain-Barre Syndrome (GBS) in 7MM - By Countries
5. Epidemiology of Guillain-Barre Syndrome (GBS) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS)
5.1.3. Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) *
5.1.4. Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) *
5.1.5. Diagnosed Cases of the Guillain-Barre Syndrome (GBS)
5.1.6. Treatable Cases of the Guillain-Barre Syndrome (GBS)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS)
5.4.3. Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) *
5.4.4. Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) *
5.4.5. Diagnosed Cases of the Guillain-Barre Syndrome (GBS)
5.4.6. Treatable Cases of the Guillain-Barre Syndrome (GBS)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS)
5.5.3. Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) *
5.5.4. Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) *
5.5.5. Diagnosed Cases of the Guillain-Barre Syndrome (GBS)
5.5.6. Treatable Cases of the Guillain-Barre Syndrome (GBS)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS)
5.6.3. Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) *
5.6.4. Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) *
5.6.5. Diagnosed Cases of the Guillain-Barre Syndrome (GBS)
5.6.6. Treatable Cases of the Guillain-Barre Syndrome (GBS)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS)
5.7.3. Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) *
5.7.4. Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) *
5.7.5. Diagnosed Cases of the Guillain-Barre Syndrome (GBS)
5.7.6. Treatable Cases of the Guillain-Barre Syndrome (GBS)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS)
5.8.3. Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) *
5.8.4. Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) *
5.8.5. Diagnosed Cases of the Guillain-Barre Syndrome (GBS)
5.8.6. Treatable Cases of the Guillain-Barre Syndrome (GBS)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS)
5.9.3. Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) *
5.9.4. Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) *
5.9.5. Diagnosed Cases of the Guillain-Barre Syndrome (GBS)
5.9.6. Treatable Cases of the Guillain-Barre Syndrome (GBS)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Guillain-Barre Syndrome (GBS)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Guillain-Barre Syndrome (GBS)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Guillain-Barre Syndrome (GBS) : 7MM Market Analysis
12.1. 7MM Market Size of Guillain-Barre Syndrome (GBS)
12.2. 7MM Percentage Share of drugs marketed for Guillain-Barre Syndrome (GBS)
12.3. 7MM Market Sales of Guillain-Barre Syndrome (GBS) by Products
13. Guillain-Barre Syndrome (GBS) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Guillain-Barre Syndrome (GBS) in United States
13.1.2. Percentage Share of drugs marketed for Guillain-Barre Syndrome (GBS) in United States
13.1.3. Market Sales of Guillain-Barre Syndrome (GBS) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Guillain-Barre Syndrome (GBS) in Germany
13.2.1.2. Percentage Share of drugs marketed for Guillain-Barre Syndrome (GBS) in Germany
13.2.1.3. Market Sales of Guillain-Barre Syndrome (GBS) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Guillain-Barre Syndrome (GBS) in France
13.2.2.2. Percentage Share of drugs marketed for Guillain-Barre Syndrome (GBS) in France
13.2.2.3. Market Sales of Guillain-Barre Syndrome (GBS) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Guillain-Barre Syndrome (GBS) in Italy
13.2.3.2. Percentage Share of drugs marketed for Guillain-Barre Syndrome (GBS) in Italy
13.2.3.3. Market Sales of Guillain-Barre Syndrome (GBS) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Guillain-Barre Syndrome (GBS) in Spain
13.2.4.2. Percentage Share of drugs marketed for Guillain-Barre Syndrome (GBS) in Spain
13.2.4.3. Market Sales of Guillain-Barre Syndrome (GBS) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Guillain-Barre Syndrome (GBS) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Guillain-Barre Syndrome (GBS) in United Kingdom
13.2.5.3. Market Sales of Guillain-Barre Syndrome (GBS) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Guillain-Barre Syndrome (GBS) in Japan
13.3.2. Percentage Share of drugs marketed for Guillain-Barre Syndrome (GBS) in Japan
13.3.3. Market Sales of Guillain-Barre Syndrome (GBS) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in United States (2016-2028)
Table 6: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in United States (2016-2028)
Table 7: Treatable Cases of the Guillain-Barre Syndrome (GBS) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in Germany (2016-2028)
Table 12: Treatable Cases of the Guillain-Barre Syndrome (GBS) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in France (2016-2028)
Table 15: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in France (2016-2028)
Table 16: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in France (2016-2028)
Table 17: Treatable Cases of the Guillain-Barre Syndrome (GBS) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in Italy (2016-2028)
Table 22: Treatable Cases of the Guillain-Barre Syndrome (GBS) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in Spain (2016-2028)
Table 27: Treatable Cases of the Guillain-Barre Syndrome (GBS) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in UK (2016-2028)
Table 31: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in UK (2016-2028)
Table 32: Treatable Cases of the Guillain-Barre Syndrome (GBS) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in Japan (2016-2028)
Table 37: Treatable Cases of the Guillain-Barre Syndrome (GBS) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Table 42:7MM- Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Table 45: United States-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Table 48: Germany-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Table 51: France-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Table 54: Italy-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Table 57: Spain-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Table 60:UK-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Table 63: Japan-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in United States (2016-2028)
Figure 7: Treatable Cases of the Guillain-Barre Syndrome (GBS) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in Germany (2016-2028)
Figure 12: Treatable Cases of the Guillain-Barre Syndrome (GBS) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in France (2016-2028)
Figure 16: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in France (2016-2028)
Figure 17: Treatable Cases of the Guillain-Barre Syndrome (GBS) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in Italy (2016-2028)
Figure 22: Treatable Cases of the Guillain-Barre Syndrome (GBS) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in Spain (2016-2028)
Figure 27: Treatable Cases of the Guillain-Barre Syndrome (GBS) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in UK (2016-2028)
Figure 32: Treatable Cases of the Guillain-Barre Syndrome (GBS) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Guillain-Barre Syndrome (GBS) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Guillain-Barre Syndrome (GBS) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Guillain-Barre Syndrome (GBS) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Guillain-Barre Syndrome (GBS) in Japan (2016-2028)
Figure 37: Treatable Cases of the Guillain-Barre Syndrome (GBS) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Figure 42:7MM- Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Figure 45: United States-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Figure 48: Germany-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Figure 51: France-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Figure 54: Italy-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Figure 57: Spain-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Figure 60:UK-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Guillain-Barre Syndrome (GBS) in USD MM (2016-2028)
Figure 63: Japan-Market Share Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Guillain-Barre Syndrome (GBS) by Therapies in USD MM (2016-2028)

  • Global Restless Legs Syndrome Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 112
    According to our LPI (LP Information) latest study, the global Restless Legs Syndrome market size was valued at US$ million in 2023. With growing demand in downstream market, the Restless Legs Syndrome is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Restless Legs Syndrome market. Restless Legs Syndrome are expected to show stable growth in the future market. However, product di......
  • Global Autism Spectrum Disorder Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 110
    Report Overview: Autism spectrum disorder is a biologically based neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests and activities. Diagnosing autism spectrum disorder (ASD) can be difficult, since there is no medical test, like a blood test, to diagnose the disorders. Doctors look at the child's behavior and development to make a diagnosis. Our report studies the market......
  • Global Epilepsy Therapeutics Market Research Report 2023
    Published: 14-Dec-2023        Price: US 2900 Onwards        Pages: 86
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Epilepsy Therapeutics market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Abbott Laboratories - Cephalon - Novartis - Pfizer - Johnson & Johnson - GlaxoSmithKline - Sanofi - Sunovion Pharmaceuticals......
  • Global Autism Spectrum Disorder Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 109
    Market Overview of Global Autism Spectrum Disorder market: According to our latest research, the global Autism Spectrum Disorder market looks promising in the next 5 years. As of 2022, the global Autism Spectrum Disorder market was estimated at USD 464.19 million, and it's anticipated to reach USD 700.88 million in 2028, with a CAGR of 7.11% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of ......
  • Global Autism Spectrum Disorder Market Status and Outlook 2023-2028
    Published: 24-Nov-2023        Price: US 3160 Onwards        Pages: 109
    Autism spectrum disorder (ASD) is a complex developmental condition that involves persistent challenges in social interaction, speech and nonverbal communication, and restricted/repetitive behaviors. The effects of ASD and the severity of symptoms are different in each person. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segmen......
  • Global Epilepsy Therapeutics Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 112
    Market Overview of Global Epilepsy Therapeutics market: According to our latest research, the global Epilepsy Therapeutics market looks promising in the next 5 years. As of 2022, the global Epilepsy Therapeutics market was estimated at USD 11157.84 million, and it's anticipated to reach USD 13510.46 million in 2028, with a CAGR of 3.24% during the forecast years. Epilepsy is a group of neurological disorders characterized by seizures. The onset of a seizure can range from a b......
  • Global Gabapentin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Oct-2023        Price: US 3380 Onwards        Pages: 98
    Market Overview of Global Gabapentin market: According to our latest research, the global Gabapentin market looks promising in the next 5 years. As of 2022, the global Gabapentin market was estimated at USD 1627.13 million, and it's anticipated to reach USD 1844.92 million in 2028, with a CAGR of 2.12% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Gabapentin market, with a sys......
  • 2023-2031 Report on Global Autism Spectrum Disorder Market by Player, Region, Type, Application and Sales Channel
    Published: 09-Oct-2023        Price: US 2500 Onwards        Pages: 89
    This report studies the Autism Spectrum Disorder market, covering market size for segment by type (Center-Based, In-Home, etc.), by application (1-14 Years Old, 15-25 Years Old, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Otsuka, Astrazeneca, Pfizer, Eli Lilly, Johnson & Johnson, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Aut......
  • Global Gabapentin Market Insights, Forecast to 2029
    Published: 27-Sep-2023        Price: US 4900 Onwards        Pages: 112
    Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain. The global Gabapentin market is projected to grow from US$ 1572.1 million in 2023 to US$ 1749.7 million by 2029, at a Compound Annual Growth Ra......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs